| |
|
|
|
|
|
 |
| |
|
³×¿À¸¶°Õ NEOMAGEN POWD.[Amomum Fruit powder , Atractylodes Rhizome powder , Cinnamon powder , Glycyrrhiza Powder , Magnesium Carbonate ,
|
|
ÀϹÝÀǾàǰ | ºñ±Þ¿©
|
|
|
| |
 |
¾Ë¸²: |
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
[A12000031]
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/1g(2002.04.01)(Ãֽžడ)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁý ´Ù¿î·Îµå]
[¿ì¸®Áý°Ç°ÁÖÄ¡ÀÇ ¹Ù·Î°¡±â]
|
| ºü¸¥Á¶È¸ |
|
| Á¦Ç°¼º»ó |
Çâ±â°¡ ÀÖ°í, Â¥°í, ¾²°í, ´Ü¸ÀÀÌ ³ª´Â Ȳ°¥»ö ¼¼ºÐ¸»
[Á¦ÇüÁ¤º¸ È®ÀÎ]
|
| Æ÷À塤À¯Åë´ÜÀ§ |
800G |
| º¸°ü¹æ¹ý |
Â÷±¤±â¹Ð¿ë±â, 24°³¿ù |
| ¾à¸®ÀÛ¿ë |
[Á¶È¸]
|
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
½Ä¿å°¨Åð(½Ä¿åºÎÁø), À§ºÎÆØ¸¸°¨, ¼ÒȺҷ®, °ú½Ä, ¼Ó¾²¸², ½Äü(À§Ã¼), ±¸¿ª, ±¸Åä, À§Åë, À§»ê°ú´Ù(À§¿°, À§.½ÊÀÌÁöÀå±Ë¾ç¿¡ °ü·ÃµÈ °Íµµ Æ÷ÇÔ), À§ºÎºÒÄè°¨, ½ÅÆ®¸²
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
[ÁÖ¼ººÐÄÚµå:279500APD ¿¡ µû¸¥ ½É»çÁöħ¿¶÷]
¼ºÀÎ 1ȸ 1½ºÇ¬(2gG), ¼Ò¾Æ 1ȸ 11~14¼¼ 2/3½ºÇ¬(1.3g), 8~10¼¼ 1/2½ºÇ¬(1g), 5~7¼¼ 1/3½ºÇ¬(0.7g), 3~4¼¼ 1/4½ºÇ¬(0.5g), 1~2¼¼ 1/5½ºÇ¬(0.5g), 1ÀÏ 3ȸ ½ÄÈÄ º¹¿ëÇÑ´Ù.
|
| ½ÅÁßÅõ¿© |
´Ù¸¥ ¾à¹°À» Åõ¿©¹Þ°í Àִ ȯÀÚ |
| ÀÌ»ó¹ÝÀÀ |
ÀÌ ¾àÀ» Åõ¿©ÇÏ´Â µ¿¾È º¯ºñ ¶Ç´Â ¼³»çÀÇ Áõ»óÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
|
| ÀϹÝÀû ÁÖÀÇ |
- Á¤ÇØÁø ¿ë¹ý, ¿ë·®À» ÁöŲ´Ù.
- ¼Ò¾Æ¿¡°Ô Åõ¿©ÇÒ °æ¿ì¿¡´Â º¸È£ÀÚÀÇ Áöµµ °¨µ¶ÇÏ¿¡ Åõ¿©ÇÑ´Ù.
- 2ÁÖ Á¤µµ Åõ¿©ÇÏ¿©µµ Áõ»óÀÇ °³¼±ÀÌ ¾øÀ» °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇϰí ÀÇ»ç, ¾à»ç¿Í »óÀÇÇÑ´Ù.
|
| ¼Ò¾Æ¿¡ ´ëÇÑ Åõ¿© |
ÀÌ ¾àÀº 3°³¿ù ¹Ì¸¸ÀÇ ¿µ¾Æ¿¡°Ô´Â Åõ¿©ÇÏÁö ¸» °Í.¶Ç 3°³¿ù ÀÌ»óÀÌ¶óµµ 1¼¼ ¹Ì¸¸ÀÇ ¿µ¾Æ¿¡°Ô´Â ºÎµæÀÌÇÑ °æ¿ì¸¦ Á¦¿ÜÇϰí´Â Åõ¿©ÇÏÁö ¸» °Í. |
| º¸°ü ¹× Ãë±Þ»óÀÇ ÁÖÀÇ |
- ¼Ò¾ÆÀÇ ¼ÕÀÌ ´êÁö ¾Ê´Â °÷¿¡ º¸°üÇÒ °Í.
- Á÷»çÀϱ¤À» ÇÇÇÏ°í µÇµµ·ÏÀÌ¸é ½À±â°¡ ÀûÀº ¼´ÃÇÑ °÷¿¡ ¹ÐÀüÇÏ¿© º¸°üÇÒ °Í.
- ¿À¿ëÀ» ¸·°í ǰÁúÀÇ º¸Á¸À» À§ÇÏ¿© ´Ù¸¥ ¿ë±â¿¡ ¹Ù²Ù¾î ³ÖÁö ¸» °Í.
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| BIT ¾àÈ¿ºÐ·ù |
¼ÒÈÁ¦ (Digestants)
|
| ATC ÄÚµå |
Antacids, other combinations / A02AX
[ÄÚµåºÐ·ù»ó¼¼¼³¸í]
[ATCÄÚµå¿¹Ãø]
|
| º¹ÁöºÎºÐ·ùÄÚµå |
233 (°ÇÀ§¼ÒÈÁ¦ )
|
| ÀǾàǰ ¹ÙÄÚµåÁ¤º¸ |
³»¿ëº¸±â
8806102870075//º´//1 ´ÜÀ§/¼ö·®: 1*8806102870099//º´//1 ´ÜÀ§/¼ö·®: 1*8806102870112//º´//1 ´ÜÀ§/¼ö·®: 1*8806102870129//º´//10 ´ÜÀ§/¼ö·®: 10*8806102870105//º´//10 ´ÜÀ§/¼ö·®: 10*8806102870082//º´//10 ´ÜÀ§/¼ö·®: 10*
|
ÁÖ¼ººÐÄÚµå ºÐ¼® ¹× Áߺ¹Ã³¹æ °ËÅä |
[ÁÖ¼ººÐÄÚµå ºÐ¼® ¹× Áߺ¹Ã³¹æ °ËÅä]
|
| Drugs By Indication |
[Àüüº¸±â]
|
| Drugs By Classification |
[Àüüº¸±â]
|
|
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| ¾à¸®ÀÛ¿ë |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ÀӺο¡´ëÇÑÅõ¿© |
| * |
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
|
|
|   |
 FDA : Cµî±Þ
|
|
| * |
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
|
| * |
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
|
|
|
| Pharmacokinetics |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸ |
[º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸]
|
| º¹¾à¶óº§ |
| À̹ÌÁö |
º¹¾à¼³¸í |
 |
º¯ºñ°¡ »ý±æ¼ö ÀÖ½À´Ï´Ù. |
|
|
| * |
º¹¾àÀ̹ÌÁö´Â ¸ðµç º¹¾àÁöµµ »çÇ×À» Ç¥½ÃÇѰÍÀº ¾Æ´Ï¸ç, Ãß°¡ÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ°Å³ª ¼öÁ¤µÉ ¼ö ÀÖ½À´Ï´Ù. |
| * |
º¹¾àÀ̹ÌÁöÀÇ Ç¥½Ã¿©ºÎ´Â ½ÇÁ¦ ¾à¹°º¹¿ë½Ã Á߿䵵¿¡ µû¸¥°ÍÀº ¾Æ´Ï¸ç ´Ü¼øÈ÷ Çã°¡Á¤º¸»ó Ű¿öµå¸¦ ±âÁØÀ¸·Î µî·ÏµÇ¾ú½À´Ï´Ù. |
| * |
±ÍÇϰ¡ º¹¾àÀ̹ÌÁö Á¤º¸¸¦ ½Å·ÚÇÔÀº ÀüÀûÀ¸·Î ±ÍÇÏÀÇ Ã¥ÀÓÀÔ´Ï´Ù. µå·°ÀÎÆ÷´Â ÀÌ¿¡ ´ëÇÑ ¾î¶°ÇÑ º¸Áõµµ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| µ¶¼ºÁ¤º¸ |
Magnesium¿¡ ´ëÇÑ µ¶¼ºÁ¤º¸ : Á¤º¸º¸±â
Ãâó: ±¹¸³µ¶¼º°úÇпø µ¶¼º¹°ÁúÁ¤º¸DB : http://www.nitr.go.kr/nitr/contents/m134200/view.do |
| Mechanism of Action |
Magnesium¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Not Available
Ginseng¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Not Available
|
| Pharmacology |
Ginseng¿¡ ´ëÇÑ Pharmacology Á¤º¸ Not Available
|
| Metabolism |
Ginseng¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Cytochrome P450 1A1 (CYP1A1)
|
| Half-life |
Ginseng¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ Not Available
|
| Absorption |
Ginseng¿¡ ´ëÇÑ Absorption Á¤º¸ Not Available
|
| Pharmacokinetics |
Magnesium CarbonateÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- Èí¼ö : °æ±¸ : ¼Ò·®ÀÇ ¸¶±×³×½·ÀÌ À§Àå°ü¿¡¼ Èí¼öµÈ´Ù.
- ¼Ò½Ç : ´ëºÎºÐÀÌ º¯¹è¼³µÇ°í, Èí¼öµÈ ¸¶±×³×½·Àº ½Å¹è¼³µÈ´Ù.
Sodium BicarbonateÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- È¿°ú ¹ßÇö ½Ã±â :
- °æ±¸ : 15ºÐ
- Á¤¸ÆÁÖ»ç : ½Å¼ÓÈ÷ ¹ßÇö
- ÀÛ¿ëÁö¼Ó ½Ã°£ :
- °æ±¸ : 1-3 ½Ã°£
- Á¤¸ÆÁÖ»ç : 8-10 ºÐ
- Èí¼ö : °æ±¸ : °æ±¸Á¦ Åõ¿©½Ã À§»êÀ» ÁßÈÇϰí ÀÌ»êÈź¼Ò¸¦ »ý¼ºÇϸç, °úµµÇÑ Áßź»êÀÌ Ç÷ÀåÀ» Èí¼öµÈ´Ù.
- ¼Ò½Ç : ½ÅÀå¿¡¼ ÀçÈí¼öµÇ¸ç, 1% ¹Ì¸¸ÀÌ ´¢¹è¼³µÊ
|
| Biotransformation |
Ginseng¿¡ ´ëÇÑ Biotransformation Á¤º¸ Not Available
|
| Toxicity |
Ginseng¿¡ ´ëÇÑ Toxicity Á¤º¸ Not Available
|
| Drug Interactions |
Magnesium¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Alendronate Formation of non-absorbable complexesCiprofloxacin Formation of non-absorbable complexesClodronate Formation of non-absorbable complexesDemeclocycline Formation of non-absorbable complexesDoxycycline Formation of non-absorbable complexesEnoxacin Formation of non-absorbable complexesEtidronic acid Formation of non-absorbable complexesGatifloxacin Formation of non-absorbable complexesGemifloxacin Formation of non-absorbable complexesGrepafloxacin Formation of non-absorbable complexesIbandronate Formation of non-absorbable complexesLevofloxacin Formation of non-absorbable complexesLomefloxacin Formation of non-absorbable complexesMethacycline Formation of non-absorbable complexesMinocycline Formation of non-absorbable complexesMoxifloxacin Formation of non-absorbable complexesNorfloxacin Formation of non-absorbable complexesOfloxacin Formation of non-absorbable complexesOxytetracycline Formation of non-absorbable complexesPefloxacin Formation of non-absorbable complexesRisedronate Formation of non-absorbable complexesTrovafloxacin Formation of non-absorbable complexesTetracycline Formation of non-absorbable complexesTemafloxacin Formation of non-absorbable complexesAmprenavir The antiacid decreases the absorption of amprenavirChloroquine The antiacid decreases the absorption of chloroquineAtazanavir This gastric pH modifier decreases the levels/effects of atazanavirDelavirdine The antiacid decreases the absorption of delavirdineDihydroquinidine barbiturate The antiacid decreases the absorption of quinidineFosamprenavir The antiacid decreases the absorption of amprenavirIndinavir The antiacid decreases the absorption of indinavirQuinidine The antiacid decreases the absorption of quindineQuinidine barbiturate The antiacid decreases the absorption of quinidinePolystyrene sulfonate Risk of alkalosis in renal impairmentRosuvastatin The antiacid decreases the absorption of rosuvastatin
Ginseng¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Amphetamine Decreased anorexic effect, may increase psychotic symptomsBenzphetamine Decreased anorexic effect, may increase psychotic symptomsDexfenfluramine Decreased anorexic effect, may increase psychotic symptomsDiethylpropion Decreased anorexic effect, may increase psychotic symptomsFenfluramine Decreased anorexic effect, may increase psychotic symptomsMazindol Decreased anorexic effect, may increase psychotic symptomsMethamphetamine Decreased anorexic effect, may increase psychotic symptomsPhendimetrazine Decreased anorexic effect, may increase psychotic symptomsDextroamphetamine Decreased anorexic effect, may increase psychotic symptomsPhenmetrazine Decreased anorexic effect, may increase psychotic symptomsPhentermine Decreased anorexic effect, may increase psychotic symptomsPhenylpropanolamine Decreased anorexic effect, may increase psychotic symptomsTranylcypromine Possible severe adverse reaction with this combinationPhenelzine Possible severe adverse reaction with this combinationIsocarboxazid Possible severe adverse reaction with this combinationPargyline Possible severe adverse reaction with this combinationBromocriptine The phenothiazine decreases the effect of bromocriptineCisapride Increased risk of cardiotoxicity and arrhythmiasGatifloxacin Increased risk of cardiotoxicity and arrhythmiasGrepafloxacin Increased risk of cardiotoxicity and arrhythmiasGuanethidine he agent decreases the effect of guanethidineLevofloxacin Increased risk of cardiotoxicity and arrhythmiasTerfenadine Increased risk of cardiotoxicity and arrhythmiasSparfloxacin Increased risk of cardiotoxicity and arrhythmiasRivastigmine Possible antagonism of actionDonepezil Possible antagonism of actionGalantamine Possible antagonism of actionMetrizamide Increased risk of convulsions
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Food Interaction |
Ginseng¿¡ ´ëÇÑ Food Interaction Á¤º¸ Not Available
|
| Drug Target |
[Drug Target]
|
| Description |
Magnesium¿¡ ´ëÇÑ Description Á¤º¸ Magnesium hydroxide is used primarily in "Milk of Magnesia", a white aqueous, mildly alkaline suspension of magnesium hydroxide formulated at about 8%w/v. Milk of magnesia is primarily used to alleviate constipation, but can also be used to relieve indigestion and heartburn. When taken internally by mouth as a laxative, the osmotic force of the magnesia suspension acts to draw fluids from the body and to retain those already within the lumen of the intestine, serving to distend the bowel, thus stimulating nerves within the colon wall, inducing peristalsis and resulting in evacuation of colonic contents.
Ginseng¿¡ ´ëÇÑ Description Á¤º¸ Ginseng is promoted as an adaptogen (a product that increases the body's resistance to stress), one which can to a certain extent be supported with reference to its anticarcinogenic and antioxidant properties. Ginseng is also known to contain phytoestrogens.
|
| Dosage Form |
Magnesium¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Aerosol OralCapsule OralLiquid IntramuscularLiquid IntravenousLiquid OralOintment TopicalPellet OralPowder OralSolution IntramuscularSolution IntravenousSolution OralSolution / drops OralSuspension OralSyrup OralTablet Oral
Ginseng¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Capsule OralLiquid OralSolution / drops OralTablet Oral
|
| Drug Category |
Magnesium¿¡ ´ëÇÑ Drug_Category Á¤º¸ Not Available
Ginseng¿¡ ´ëÇÑ Drug_Category Á¤º¸ Not Available
|
| Smiles String Canonical |
Magnesium¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ [Mg++]
Ginseng¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ Not Available
|
| Smiles String Isomeric |
Magnesium¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ [Mg++]
Ginseng¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ Not Available
|
| InChI Identifier |
Magnesium¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/Mg/q+2
Ginseng¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ Not Available
|
| Chemical IUPAC Name |
Magnesium¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ magnesium(+2) cation
Ginseng¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ Not Available
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2016-05-10
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
[ÀǾàǰº´¿ë/¿¬·É´ë±Ý±â °í½Ã±Ù°Å·Î ¹Ù·Î°¡±â] Á¦¸ñ ¾øÀ½
2008³â 8¿ù 1ÀÏ ¾à°¡ÈÀÏ»ó 8¿ù´Þ ½Å±ÔµîÀç ¹× »èÁ¦µÇ´Â ǰ¸ñ Æ÷ÇÔÇÑ º´¿ë¿¬·É ±Ý±â ǰ¸ñ¸®½ºÆ® ±âÁØ
1. ÇöÀç °Ë»öÇÑ Á¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â Á¦Ç° Á¸Àç¿©ºÎ ¹× °Ë»ö
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 Á¦Ç°³»¿ª °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
2. ¿¬·É´ë±Ý±â Á¸Àç¿©ºÎ
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ ¿¬·É±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
|
|
|
|